Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial May 05, 2025 7:00am EDT
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference Apr 23, 2025 7:30am EDT
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort Feb 20, 2025 7:32am EST
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility Feb 13, 2025 4:30pm EST
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial Feb 12, 2025 7:00am EST
